Aurobindo Pharma shares in focus after USFDA issues observations

Aurobindo Pharma shares stayed in focus after the USFDA issued 11 observations following an inspection at one of its manufacturing facilities. The company said it would respond within the prescribed timeline. Investors tracked the development closely, as regulatory compliance outcomes may impact the approvals and export momentum, and near-term sentiment for the stock in domestic and overseas markets going ahead.